JP2002503477A - 抗ウイルスベクター - Google Patents
抗ウイルスベクターInfo
- Publication number
- JP2002503477A JP2002503477A JP2000531578A JP2000531578A JP2002503477A JP 2002503477 A JP2002503477 A JP 2002503477A JP 2000531578 A JP2000531578 A JP 2000531578A JP 2000531578 A JP2000531578 A JP 2000531578A JP 2002503477 A JP2002503477 A JP 2002503477A
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- viral
- virus
- hiv
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000013598 vector Substances 0.000 title claims description 99
- 230000000840 anti-viral effect Effects 0.000 title description 4
- 239000002773 nucleotide Substances 0.000 claims abstract description 100
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 100
- 230000003612 virological effect Effects 0.000 claims abstract description 71
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 65
- 239000002245 particle Substances 0.000 claims abstract description 61
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 28
- 230000007017 scission Effects 0.000 claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 claims abstract description 24
- 229920001184 polypeptide Polymers 0.000 claims abstract description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 21
- 239000013603 viral vector Substances 0.000 claims abstract description 21
- 208000036142 Viral infection Diseases 0.000 claims abstract description 8
- 230000009385 viral infection Effects 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 99
- 108090000994 Catalytic RNA Proteins 0.000 claims description 97
- 102000053642 Catalytic RNA Human genes 0.000 claims description 97
- 108091092562 ribozyme Proteins 0.000 claims description 97
- 241000700605 Viruses Species 0.000 claims description 81
- 238000004806 packaging method and process Methods 0.000 claims description 67
- 230000001177 retroviral effect Effects 0.000 claims description 38
- 230000014509 gene expression Effects 0.000 claims description 36
- 108020004705 Codon Proteins 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 108010078428 env Gene Products Proteins 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 102100034353 Integrase Human genes 0.000 claims description 10
- 241000713666 Lentivirus Species 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 230000004048 modification Effects 0.000 claims description 9
- 238000012986 modification Methods 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 8
- 108010089520 pol Gene Products Proteins 0.000 claims description 8
- 101710177291 Gag polyprotein Proteins 0.000 claims description 7
- 239000003184 complementary RNA Substances 0.000 claims description 7
- 101710125418 Major capsid protein Proteins 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 69
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 42
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 26
- 241001430294 unidentified retrovirus Species 0.000 description 26
- 239000013612 plasmid Substances 0.000 description 19
- 230000036436 anti-hiv Effects 0.000 description 17
- 108091026890 Coding region Proteins 0.000 description 16
- 230000000692 anti-sense effect Effects 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108700010070 Codon Usage Proteins 0.000 description 13
- 102100034349 Integrase Human genes 0.000 description 13
- 230000006870 function Effects 0.000 description 11
- 230000010076 replication Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 101710091045 Envelope protein Proteins 0.000 description 9
- 101710188315 Protein X Proteins 0.000 description 9
- 238000001415 gene therapy Methods 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 238000010361 transduction Methods 0.000 description 8
- 230000026683 transduction Effects 0.000 description 8
- 208000031886 HIV Infections Diseases 0.000 description 7
- 108700001624 vesicular stomatitis virus G Proteins 0.000 description 7
- 208000037357 HIV infectious disease Diseases 0.000 description 6
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 6
- 241000714177 Murine leukemia virus Species 0.000 description 6
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 108020005544 Antisense RNA Proteins 0.000 description 5
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 5
- 241000251131 Sphyrna Species 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 108700004025 env Genes Proteins 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000003146 transient transfection Methods 0.000 description 5
- 241000713730 Equine infectious anemia virus Species 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 108700004029 pol Genes Proteins 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108091027305 Heteroduplex Proteins 0.000 description 3
- 101710203526 Integrase Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000713311 Simian immunodeficiency virus Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- -1 antibodies Proteins 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 108700004026 gag Genes Proteins 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 230000001566 pro-viral effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 241000713840 Avian erythroblastosis virus Species 0.000 description 2
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 241000714475 Fujinami sarcoma virus Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 101150098638 RNASE1 gene Proteins 0.000 description 2
- 206010038997 Retroviral infections Diseases 0.000 description 2
- 102100039832 Ribonuclease pancreatic Human genes 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 241000713325 Visna/maedi virus Species 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 101150030339 env gene Proteins 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 2
- 108090001052 hairpin ribozyme Proteins 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 101150076131 rib-1 gene Proteins 0.000 description 2
- 101150021392 rib-2 gene Proteins 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000000605 viral structure Anatomy 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000713834 Avian myelocytomatosis virus 29 Species 0.000 description 1
- 241000714235 Avian retrovirus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 1
- 102100033029 Carbonic anhydrase-related protein 11 Human genes 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 102100033779 Collagen alpha-4(IV) chain Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101000867841 Homo sapiens Carbonic anhydrase-related protein 11 Proteins 0.000 description 1
- 101000710870 Homo sapiens Collagen alpha-4(IV) chain Proteins 0.000 description 1
- 101100283445 Homo sapiens GNA11 gene Proteins 0.000 description 1
- 101001075218 Homo sapiens Gastrokine-1 Proteins 0.000 description 1
- 108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101000783705 Myxoma virus (strain Uriarra) Envelope protein A28 homolog Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710150344 Protein Rev Proteins 0.000 description 1
- 101150078370 RIB3 gene Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 108091026838 U1 spliceosomal RNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9803351.7 | 1998-02-17 | ||
| GBGB9803351.7A GB9803351D0 (en) | 1998-02-17 | 1998-02-17 | Anti-viral vectors |
| PCT/GB1999/000325 WO1999041397A1 (en) | 1998-02-17 | 1999-02-17 | Anti-viral vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002503477A true JP2002503477A (ja) | 2002-02-05 |
| JP2002503477A5 JP2002503477A5 (enExample) | 2006-06-08 |
Family
ID=10827139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000531578A Ceased JP2002503477A (ja) | 1998-02-17 | 1999-02-17 | 抗ウイルスベクター |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6541248B1 (enExample) |
| EP (2) | EP1054988B1 (enExample) |
| JP (1) | JP2002503477A (enExample) |
| CN (1) | CN1297486A (enExample) |
| AT (1) | ATE358732T1 (enExample) |
| AU (1) | AU757284B2 (enExample) |
| CA (1) | CA2321097A1 (enExample) |
| DE (1) | DE69935714T2 (enExample) |
| GB (1) | GB9803351D0 (enExample) |
| WO (1) | WO1999041397A1 (enExample) |
Families Citing this family (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| JP2003523721A (ja) | 1998-12-31 | 2003-08-12 | カイロン コーポレイション | 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用 |
| EP1535995A1 (en) * | 1998-12-31 | 2005-06-01 | Chiron Corporation | Polynucleotides encoding the antigenic HIV type C env polypeptide and uses thereof |
| US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| EP2206785A1 (en) | 1998-12-31 | 2010-07-14 | Novartis Vaccines and Diagnostics, Inc. | Improved expression of HIV polypeptides and production of virus-like particles |
| GB9906177D0 (en) * | 1999-03-17 | 1999-05-12 | Oxford Biomedica Ltd | Anti-viral vectors |
| CN101586106B (zh) * | 1999-11-16 | 2015-04-01 | 真那特股份公司 | Hiv-1亚型间(c/b’)基因组和其用途 |
| JP2003526367A (ja) * | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | Ｒｎａ干渉の方法とｒｎａ干渉組成物 |
| US8202846B2 (en) * | 2000-03-16 | 2012-06-19 | Cold Spring Harbor Laboratory | Methods and compositions for RNA interference |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| EP1315839B9 (en) * | 2000-09-01 | 2009-08-12 | Gen-Probe Incorporated | Amplification of hiv-1 sequences for detection of sequences associated with drug-resistance mutations |
| CA2422882A1 (en) * | 2000-09-15 | 2002-03-21 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
| IL154987A0 (en) * | 2000-09-22 | 2003-10-31 | Virxsys | Conditionally replicating viral vectors and their use |
| GB0024550D0 (enExample) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
| MXPA03006624A (es) | 2001-01-25 | 2004-11-12 | Virxsys Corp | Metodos y composiciones para la identificacion de la funcion de genes. |
| CA2344208A1 (en) | 2001-04-30 | 2002-10-30 | Oxford Biomedica (Uk) Limited | Method |
| WO2003004620A2 (en) | 2001-07-05 | 2003-01-16 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| US6835568B2 (en) | 2001-10-30 | 2004-12-28 | Virxsys Corporation | Regulated nucleic acid expression system |
| JP4598398B2 (ja) * | 2002-02-01 | 2010-12-15 | オックスフォード バイオメディカ （ユーケー） リミテッド | ウイルスベクター |
| GB0526211D0 (en) * | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| CA2723320C (en) | 2007-05-04 | 2019-06-11 | University Health Network | Il-12 immunotherapy for cancer |
| US20090088625A1 (en) * | 2007-10-01 | 2009-04-02 | Kenneth Oosting | Photonic Based Non-Invasive Surgery System That Includes Automated Cell Control and Eradication Via Pre-Calculated Feed-Forward Control Plus Image Feedback Control For Targeted Energy Delivery |
| WO2009153563A1 (en) | 2008-06-18 | 2009-12-23 | Oxford Biomedica (Uk) Limited | Virus purification |
| US20120310140A1 (en) | 2010-12-01 | 2012-12-06 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
| GB201118636D0 (en) | 2011-10-28 | 2011-12-07 | Oxford Biomedica Ltd | Nucleotide sequence |
| US10106816B2 (en) * | 2012-12-14 | 2018-10-23 | Case Western Reserve University | Genomic RNA packaging enhancer element |
| EP2986635B1 (en) | 2013-04-18 | 2018-10-03 | Fondazione Telethon | Effective delivery of large genes by dual aav vectors |
| GB201318804D0 (en) | 2013-10-24 | 2013-12-11 | Adaptimmune Ltd | Vectors for transgene expression |
| GB201322798D0 (en) | 2013-12-20 | 2014-02-05 | Oxford Biomedica Ltd | Production system |
| AU2015316480B2 (en) | 2014-09-15 | 2021-02-04 | Ospedale San Raffaele S.R.L. | Chimeric antigen receptors |
| GB201418965D0 (enExample) | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| US10221398B2 (en) | 2014-12-16 | 2019-03-05 | C3J Therapeutics, Inc. | Compositions of and methods for in vitro viral genome engineering |
| GB201519086D0 (en) | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
| EP3380620B1 (en) | 2015-11-23 | 2024-07-03 | Novartis AG | Optimized lentiviral transfer vectors and uses thereof |
| US20190017096A1 (en) | 2016-03-10 | 2019-01-17 | Nightstarx Limited | Prenylation assay |
| EP3318285A1 (en) | 2016-11-08 | 2018-05-09 | Oxford University Innovation Limited | Treatment of eye disease |
| EP3548618A1 (en) | 2016-12-01 | 2019-10-09 | Nestec S.A. | Methods of modulating fam46a |
| EP3375876A1 (en) | 2017-03-13 | 2018-09-19 | Evonetix Ltd | Method for producing double stranded polynucleotides based on oligonucleotides with selected and different melting temperatures |
| US20210189389A1 (en) | 2017-03-31 | 2021-06-24 | Societe Des Produits Nestle S.A. | Methods of modulating ank1 |
| FI3612624T3 (fi) * | 2017-04-21 | 2024-12-04 | Ospedale San Raffaele Srl | Geeniterapia |
| CN110785432B (zh) | 2017-04-24 | 2024-12-27 | 圣拉斐尔医院有限责任公司 | Tcr和肽 |
| WO2019068854A1 (en) | 2017-10-06 | 2019-04-11 | Ospedale San Raffaele S.R.L. | GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS |
| CA3083898A1 (en) | 2017-10-17 | 2019-04-25 | Nightstarx Limited | Prenylation assay |
| US20200385736A1 (en) | 2017-11-21 | 2020-12-10 | Societe Des Produits Nestle S.A. | Methods of modulating alk |
| EP3633040B1 (en) | 2017-12-22 | 2023-06-07 | Oxford BioMedica (UK) Limited | Retroviral vector |
| WO2019134866A1 (en) | 2018-01-03 | 2019-07-11 | Molmed Spa | Chimeric antigen receptors containing optimal spacer region |
| KR20210003810A (ko) | 2018-04-18 | 2021-01-12 | 유씨엘 비즈니스 리미티드 | Treg 세포의 억제 특성을 향상시키기 위한 방법 |
| SG11202011015QA (en) | 2018-05-15 | 2020-12-30 | Flagship Pioneering Innovations V Inc | Fusosome compositions and uses thereof |
| EP3794121A1 (en) | 2018-05-17 | 2021-03-24 | Société des Produits Nestlé S.A. | Methods of modulating nkx6.3 |
| WO2019229109A1 (en) | 2018-05-30 | 2019-12-05 | Glycostem Therapeutics B.V. | Car nk cells |
| CN112955174A (zh) | 2018-07-09 | 2021-06-11 | 旗舰先锋创新V股份有限公司 | 融合剂脂质体组合物和其用途 |
| GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| GB201817821D0 (en) | 2018-10-31 | 2018-12-19 | Ospedale San Raffaele Srl | TCR and peptides |
| US20230048166A1 (en) | 2018-11-14 | 2023-02-16 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for hematopoietic stem cell delivery |
| AU2019378883A1 (en) | 2018-11-14 | 2021-06-03 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for T cell delivery |
| AU2019378881A1 (en) | 2018-11-14 | 2021-06-03 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for CNS delivery |
| AU2019400930A1 (en) | 2018-12-19 | 2021-07-01 | King's College London | Immunotherapeutic methods and compositions |
| GB201900687D0 (en) | 2019-01-17 | 2019-03-06 | King S College London | Immunotherapeutic methods and compositions |
| GB201902277D0 (en) | 2019-02-19 | 2019-04-03 | King S College London | Therapeutic agents |
| CA3133188A1 (en) | 2019-03-10 | 2020-09-17 | Oxford Biomedica (Uk) Limited | Gene therapy compositions and methods for treating parkinson's disease |
| GB201905301D0 (en) | 2019-04-15 | 2019-05-29 | Ospedale San Raffaele Srl | Gene therapy |
| GB201907493D0 (en) | 2019-05-28 | 2019-07-10 | Ospedale San Raffaele | Agents and methods for treating viral infections |
| GB201912515D0 (en) | 2019-08-30 | 2019-10-16 | King S College London | Engineered regulatory T cell |
| WO2021046143A1 (en) | 2019-09-03 | 2021-03-11 | Sana Biotechnology, Inc. | Cd24-associated particles and related methods and uses thereof |
| KR20220097492A (ko) | 2019-11-12 | 2022-07-07 | 옥스포드 바이오메디카(유케이) 리미티드 | 생산 시스템 |
| EP4103723A1 (en) | 2020-02-13 | 2022-12-21 | Oxford BioMedica (UK) Limited | Production of lentiviral vectors |
| GB2609103A (en) | 2020-02-25 | 2023-01-25 | Quell Therapeutics Ltd | Chimeric receptors for use in engineered cells |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2021181108A1 (en) | 2020-03-13 | 2021-09-16 | Oxford Biomedica (Uk) Limited | Lentiviral vectors |
| JP2023521663A (ja) | 2020-03-31 | 2023-05-25 | サナ バイオテクノロジー，インコーポレイテッド | 標的化脂質粒子及び組成物ならびにその使用 |
| CN116096430A (zh) | 2020-04-27 | 2023-05-09 | 衣阿华大学研究基金会 | 用于治疗囊性纤维化的组合物和方法 |
| GB202007169D0 (en) | 2020-05-14 | 2020-07-01 | Ospedale San Raffaele Srl | Epidermal growth factor receptor |
| GB202007199D0 (en) | 2020-05-15 | 2020-07-01 | Oxford Biomedica Ltd | Viral vector production |
| WO2021236852A1 (en) | 2020-05-20 | 2021-11-25 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
| GB202013477D0 (en) | 2020-08-27 | 2020-10-14 | Quell Therapeutics Ltd | Nucleic acid constructs for expressing polypeptides in cells |
| WO2022047316A1 (en) | 2020-08-28 | 2022-03-03 | Sana Biotechnology, Inc. | Modified anti-viral binding agents |
| GB202017725D0 (en) | 2020-11-10 | 2020-12-23 | Oxford Biomedica Ltd | Method |
| GB202018657D0 (en) | 2020-11-26 | 2021-01-13 | Ospedale San Raffaele Srl | Agents and methods for increasing liver immune response |
| WO2022136874A1 (en) | 2020-12-23 | 2022-06-30 | Quell Therapeutics Limited | Inducible signalling protein |
| JP2024503027A (ja) | 2021-01-11 | 2024-01-24 | サナ バイオテクノロジー，インコーポレイテッド | Ｃｄ８標的ウイルスベクターの使用方法 |
| AU2022213505A1 (en) | 2021-02-01 | 2023-09-07 | Epsilen Bio S.R.L. | Gene silencing |
| US20240101623A1 (en) | 2021-02-15 | 2024-03-28 | Ospedale San Raffaele S.R.L. | Epigenetic silencing for treatment of cancer |
| GB202102637D0 (en) | 2021-02-24 | 2021-04-07 | Quell Therapeutics Ltd | Engineered regulatory t cell |
| WO2022238556A1 (en) | 2021-05-12 | 2022-11-17 | Fondazione Telethon | Vector system |
| AU2022280957A1 (en) | 2021-05-28 | 2023-11-30 | Sana Biotechnology, Inc. | Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses |
| EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| EP4405385A1 (en) | 2021-09-21 | 2024-07-31 | Quell Therapeutics Limited | Anti-trem2 chimeric antigen receptor |
| WO2023047098A2 (en) | 2021-09-21 | 2023-03-30 | Quell Therapeutics Ltd | Anti-p75ntr chimeric antigen receptor |
| GB202114528D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
| GB202114534D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Novel viral regulatory elements |
| GB202114530D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Retroviral vectors |
| GB202114532D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral Vectors |
| GB202114529D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
| US20250000966A1 (en) * | 2021-10-13 | 2025-01-02 | The Cleveland Clinic Foundation | Mrna vaccine design via the alteration of codon usage |
| WO2023077107A1 (en) | 2021-10-29 | 2023-05-04 | Sana Biotechnology, Inc. | Methods and reagents for amplifying viral vector nucleic acid products |
| GB202117298D0 (en) | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
| US20250059560A1 (en) | 2021-12-16 | 2025-02-20 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| US20240408192A1 (en) | 2021-12-17 | 2024-12-12 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
| WO2023115039A2 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
| EP4453022A1 (en) | 2021-12-22 | 2024-10-30 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| JP2025500618A (ja) | 2022-01-05 | 2025-01-09 | ギャラ セラピューティクス ソシエダ リミタダ | 抗ｃｄ８４抗体およびキメラ抗原受容体 |
| EP4209511A1 (en) | 2022-01-05 | 2023-07-12 | Gyala Therapeutics Sociedad Limitada | Anti-cd84 antibodies amd chimeric antigen receptors |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4472646A1 (en) | 2022-02-01 | 2024-12-11 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| EP4269426A1 (en) | 2022-04-29 | 2023-11-01 | Ospedale San Raffaele S.r.l. | Gene therapy |
| EP4303226A1 (en) | 2022-07-08 | 2024-01-10 | Ospedale San Raffaele S.r.l. | Transgene cassettes and epigenetic silencers for the treatment of disorders |
| AU2023304708A1 (en) | 2022-07-08 | 2025-01-23 | Consiglio Nazionale Delle Ricerche | Transgene cassettes |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024033544A1 (en) | 2022-08-12 | 2024-02-15 | Ospedale San Raffaele S.R.L. | Deglycosylation of native glycoproteins expressed on a tumor cell surface |
| GB202211935D0 (en) | 2022-08-16 | 2022-09-28 | Oxford Biomedica Ltd | envelope proteins |
| WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| EP4590688A1 (en) | 2022-09-21 | 2025-07-30 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| EP4602174A1 (en) | 2022-10-13 | 2025-08-20 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| EP4615492A1 (en) | 2022-11-08 | 2025-09-17 | Ospedale San Raffaele S.r.l. | Polynucleotide and vector |
| WO2024100294A1 (en) | 2022-11-11 | 2024-05-16 | Ospedale San Raffaele S.R.L. | Cdh17 car |
| GB202217541D0 (en) | 2022-11-24 | 2023-01-11 | Quell Therapeutics Ltd | Recombinant receptor |
| EP4627096A1 (en) | 2022-12-02 | 2025-10-08 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024133472A1 (en) | 2022-12-22 | 2024-06-27 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| EP4651887A1 (en) | 2023-01-16 | 2025-11-26 | Ospedale San Raffaele S.r.l. | T-cell receptors |
| CN120981484A (zh) | 2023-01-23 | 2025-11-18 | 汉诺威医学院 | 抗entpd3嵌合抗原受体 |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| KR20250165594A (ko) | 2023-02-07 | 2025-11-26 | 퀠 테라퓨틱스 리미티드 | Treg 세포의 배양 방법 |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| CN120981564A (zh) | 2023-03-17 | 2025-11-18 | 圭尔医疗有限公司 | 调节性t细胞疗法 |
| WO2024194223A2 (en) | 2023-03-17 | 2024-09-26 | Ospedale San Raffaele S.R.L. | Gene therapy |
| WO2024194355A1 (en) | 2023-03-20 | 2024-09-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| AU2024241563A1 (en) | 2023-03-22 | 2025-10-09 | Consiglio Nazionale Delle Ricerche | Gene therapy |
| WO2024194649A1 (en) | 2023-03-22 | 2024-09-26 | Quell Therapeutics Limited | Engineered t cells and uses thereof |
| WO2024194642A1 (en) | 2023-03-22 | 2024-09-26 | Quell Therapeutics Limited | Engineered t regulatory cell |
| WO2024220560A1 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Engineered protein g fusogens and related lipid particles and methods thereof |
| WO2024220574A1 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Universal protein g fusogens and adapter systems thereof and related lipid particles and uses |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| GB202307366D0 (en) | 2023-05-17 | 2023-06-28 | Ospedale San Raffaele Srl | Vector |
| WO2024243340A1 (en) | 2023-05-23 | 2024-11-28 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| WO2024259299A1 (en) | 2023-06-14 | 2024-12-19 | The Broad Institute, Inc. | Compositions and methods for identification of vhh antibodies that bind a target antigen |
| WO2024261480A1 (en) | 2023-06-21 | 2024-12-26 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| WO2025003481A2 (en) | 2023-06-28 | 2025-01-02 | Ospedale San Raffaele S.R.L. | T-cell receptors |
| WO2025032194A1 (en) | 2023-08-08 | 2025-02-13 | Ospedale San Raffaele S.R.L. | T-cell receptors |
| IT202300022191A1 (it) | 2023-10-24 | 2025-04-24 | Fond Telethon Ets | Mezzi e metodi per la modifica genetica di uba1 |
| GB202316264D0 (en) | 2023-10-24 | 2023-12-06 | Ospendale San Raffaele S R L | Gene therapy |
| WO2025109189A1 (en) | 2023-11-24 | 2025-05-30 | Ospedale San Raffaele S.R.L. | Engineered regulatory t cells and uses thereof |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| EP4640830A1 (en) | 2024-04-23 | 2025-10-29 | Fondazione Telethon ETS | Means and methods for safe and efficient gene editing in cells |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06335392A (ja) * | 1993-02-25 | 1994-12-06 | Ortho Pharmaceut Corp | Ｈｉｖ阻害性アンチセンスおよび他のヌクレオチド配列を含有する発現構成体、レトロウイルスのベクターおよびそれを含有する組換えレトロウイルス |
| WO1996009378A1 (en) * | 1994-09-19 | 1996-03-28 | The General Hospital Corporation | Overexpression of mammalian and viral proteins |
| EP0759471A1 (en) * | 1994-05-10 | 1997-02-26 | Hisamitsu Pharmaceutical Co., Inc. | Recombinant human immunodeficiency virus vector and process for producing the same |
| WO1997011086A1 (en) * | 1995-09-22 | 1997-03-27 | The General Hospital Corporation | High level expression of proteins |
| WO1997020060A1 (en) * | 1995-11-28 | 1997-06-05 | The Johns Hopkins University School Of Medicine | Conditionally replicating viral vectors and their use |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH083062B2 (ja) | 1987-07-29 | 1996-01-17 | ビーエーエスエフ ラツケ ウント フアルベン アクチエンゲゼルシヤフト | 陰極で析出可能な合成樹脂を含有する水性電気浸漬ラツカー浴及び電気伝導性基材の被覆法 |
| DE69434860T2 (de) | 1993-02-22 | 2007-03-15 | The Rockefeller University | Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion |
| US5834256A (en) | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| US6013517A (en) * | 1994-05-09 | 2000-01-11 | Chiron Corporation | Crossless retroviral vectors |
| EP0772689B1 (en) | 1994-05-09 | 2007-12-19 | Oxford Biomedica (UK) Limited | Retroviral vectors having a reduced recombination rate |
| CA2221769C (en) * | 1995-05-26 | 2003-07-01 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for quantitatively determining an antibody having the ability to inhibit the activity of a reverse transcriptase |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| GB9525639D0 (en) | 1995-12-15 | 1996-02-14 | Isis Innovation | Improved retroviral vectors |
| PT880594E (pt) | 1996-01-23 | 2003-03-31 | Oxford Biomedica Ltd | Vector retroviral e sua utilizacao em terapia genica |
| PL328730A1 (en) | 1996-02-22 | 1999-02-15 | Merck & Co Inc | Synthetic hiv genes |
| WO1997042338A1 (en) | 1996-05-06 | 1997-11-13 | Chiron Corporation | Crossless retroviral vectors |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| AU725143B2 (en) | 1996-10-17 | 2000-10-05 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
| GB9621680D0 (en) | 1996-10-17 | 1996-12-11 | Oxford Biomedica Ltd | Lentiviral vectors |
| IL131131A0 (en) * | 1997-02-07 | 2001-01-28 | Merck & Co Inc | Synthetic hiv gag genes |
| US6696291B2 (en) * | 1997-02-07 | 2004-02-24 | Merck & Co., Inc. | Synthetic HIV gag genes |
| JP4390860B2 (ja) * | 1997-05-13 | 2009-12-24 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | レンチウイルスをベースにした遺伝子転移ベクター |
| ATE528405T1 (de) | 1997-12-22 | 2011-10-15 | Oxford Biomedica Ltd | Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| US6958226B1 (en) * | 1998-09-11 | 2005-10-25 | The Children's Medical Center Corp. | Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins |
| WO2000015819A1 (en) | 1998-09-11 | 2000-03-23 | The Children's Medical Center Corporation | Packaging cell lines for hiv-derived retroviral vector particles |
| GB9825524D0 (en) | 1998-11-20 | 1999-01-13 | Oxford Biomedica Ltd | Vector |
| EP2206785A1 (en) | 1998-12-31 | 2010-07-14 | Novartis Vaccines and Diagnostics, Inc. | Improved expression of HIV polypeptides and production of virus-like particles |
| GB9906177D0 (en) | 1999-03-17 | 1999-05-12 | Oxford Biomedica Ltd | Anti-viral vectors |
| HUP0201019A2 (en) | 1999-04-26 | 2002-08-28 | Leuven K U Res & Dev | Synthetic gene for expressing active retroviral protein in eukaryotes |
| GB9923558D0 (en) | 1999-10-05 | 1999-12-08 | Oxford Biomedica Ltd | Producer cell |
-
1998
- 1998-02-17 GB GBGB9803351.7A patent/GB9803351D0/en not_active Ceased
-
1999
- 1999-02-17 AT AT99904956T patent/ATE358732T1/de not_active IP Right Cessation
- 1999-02-17 WO PCT/GB1999/000325 patent/WO1999041397A1/en not_active Ceased
- 1999-02-17 AU AU25274/99A patent/AU757284B2/en not_active Expired
- 1999-02-17 EP EP99904956A patent/EP1054988B1/en not_active Expired - Lifetime
- 1999-02-17 EP EP07000193A patent/EP1790658A3/en not_active Withdrawn
- 1999-02-17 DE DE69935714T patent/DE69935714T2/de not_active Expired - Lifetime
- 1999-02-17 CA CA002321097A patent/CA2321097A1/en not_active Abandoned
- 1999-02-17 JP JP2000531578A patent/JP2002503477A/ja not_active Ceased
- 1999-02-17 CN CN99805126A patent/CN1297486A/zh active Pending
-
2000
- 2000-04-20 US US09/552,950 patent/US6541248B1/en not_active Expired - Lifetime
-
2003
- 2003-01-27 US US10/351,938 patent/US7790419B2/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06335392A (ja) * | 1993-02-25 | 1994-12-06 | Ortho Pharmaceut Corp | Ｈｉｖ阻害性アンチセンスおよび他のヌクレオチド配列を含有する発現構成体、レトロウイルスのベクターおよびそれを含有する組換えレトロウイルス |
| EP0759471A1 (en) * | 1994-05-10 | 1997-02-26 | Hisamitsu Pharmaceutical Co., Inc. | Recombinant human immunodeficiency virus vector and process for producing the same |
| WO1996009378A1 (en) * | 1994-09-19 | 1996-03-28 | The General Hospital Corporation | Overexpression of mammalian and viral proteins |
| WO1997011086A1 (en) * | 1995-09-22 | 1997-03-27 | The General Hospital Corporation | High level expression of proteins |
| WO1997020060A1 (en) * | 1995-11-28 | 1997-06-05 | The Johns Hopkins University School Of Medicine | Conditionally replicating viral vectors and their use |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9803351D0 (en) | 1998-04-15 |
| AU757284B2 (en) | 2003-02-13 |
| DE69935714T2 (de) | 2007-12-27 |
| AU2527499A (en) | 1999-08-30 |
| ATE358732T1 (de) | 2007-04-15 |
| EP1054988B1 (en) | 2007-04-04 |
| US20040009603A1 (en) | 2004-01-15 |
| CA2321097A1 (en) | 1999-08-19 |
| WO1999041397A1 (en) | 1999-08-19 |
| CN1297486A (zh) | 2001-05-30 |
| US6541248B1 (en) | 2003-04-01 |
| DE69935714D1 (de) | 2007-05-16 |
| EP1790658A3 (en) | 2007-09-12 |
| EP1790658A2 (en) | 2007-05-30 |
| US7790419B2 (en) | 2010-09-07 |
| EP1054988A1 (en) | 2000-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1054988B1 (en) | Anti-viral vectors | |
| US6168953B1 (en) | Genetic antiviral agents and methods for their use | |
| EP1192265A1 (en) | Anti-viral vectors | |
| EP3060668B2 (en) | Vectors for transgene expression | |
| US5885806A (en) | Methods to prepare conditionally replicating viral vectors | |
| EP1380650B1 (en) | Conditionally replicating viral vectors and their use | |
| Mautino et al. | Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA | |
| EP1180167B1 (en) | In vivo selection method for determining inhibitory rna molecules | |
| JP2002510204A (ja) | バキュロウイルス発現系内で作製されるレトロウイルスベクター粒子 | |
| US20020102537A1 (en) | Retroviral production | |
| HK1223124B (en) | Vectors for transgene expression | |
| HK1060152B (en) | Conditionally replicating viral vectors and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060405 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090210 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090507 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090514 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090810 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091201 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100330 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100412 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100622 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20101026 |